EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

EXODUS 支持的细胞外囊泡高通量多组学分析用于临床前阿尔茨海默病的诊断

• 批准号: 10604194
• 负责人: Yuchao Chen
• 金额: $ 11.04万
• 依托单位: WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10604194
• 关键词: Address; Aliquot; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease patient; Alzheimer' s disease therapy; Alzheimer’s disease biomarker; Bioinformatics; Biological Assay; Biological Markers; Biomedical Technology; Blood; Blood - brain barrier anatomy; Blood Circulation; Brain Injuries; CLIA certified; Cerebrospinal Fluid; Clinical; Communities; Data; Devices; Diagnosis; Diagnostic tests; Early Diagnosis; Face; Goals; Intervention; Label; Laboratories; Malignant neoplasm of urinary bladder; Mediator of activation protein; Methodology; Molecular; Neurodegenerative Disorders; Neurons; Outcome; Pathogenesis; Pathologic; Patients; Performance; Peripheral; Phase; Plasma; Proteomics; Psyche structure; Reproducibility; Research; Research Personnel; Running; Sampling; Small Business Innovation Research Grant; Source; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Speed; Techniques; Technology; Time; Ultrafiltration; Validation; Variant; acute pancreatitis; aging population; base; biomarker discovery; biomarker panel; design; extracellular vesicles; flexibility; global health; improved; innovation; lipidomics; liquid biopsy; methylomics; multiple omics; novel; novel marker; novel strategies; phase 1 study; pre-clinical; predictive modeling; symptom treatment; targeted treatment; technological innovation; testing services; transcriptomics

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However, researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.

项目概要/摘要 阿尔茨海默氏病（AD）是最普遍的神经退行性疾病，已引起全球性的重大疾病 人口老龄化带来的健康问题。在不可逆的脑损伤或精神损伤之前早期诊断 AD 衰退对于及时干预、对症治疗和改善患者功能至关重要。积累中 研究表明，神经元来源的细胞外囊泡 (EV) 是 AD 的重要生物标志物。然而， 研究人员在电动汽车的有效分离和准确分析方面面临着重大挑战，限制了广泛的研究 EVs在AD早期诊断或靶向治疗中的研究和应用。 WellSIM 提议开发和 验证基于我们革命性的 EXODUS 技术的高通量平台和工作流程，以实现可靠且可靠的结果 可重复地从血浆和脑脊液中分离和分析 EV，具有无与伦比的通量、纯度、产量和 敏感性。基于hi-EXODUS-NGS和hi-EXODUS-MS综合分析，转录组和蛋白质组 将开发 EV 分析，以发现和检测 EV 衍生的多类生物标志物，用于 AD 诊断。